Adlai Nortye Ltd. has received approval to begin a Phase I clinical trial in Australia for AN4035, a novel antibody drug conjugate targeting CEACAM5-enriched RAS-addicted tumors. This first-in-class pan-RAS(ON) inhibitor ADC aims to deliver targeted cancer treatment with reduced systemic toxicity. The trial will assess safety, tolerability, and preliminary efficacy, with patient dosing expected to start in the second half of 2026. IND applications are also underway in the US and China.
Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance by about $200 million due to slower growth after initial demand in the ATTR-CM market. This announcement led to a sharp drop in its stock price by more than 28%, causing significant lo...
Stripe is set to acquire OpenRouter, an AI gateway startup that offers access to multiple AI models, for more than $7 billion. OpenRouter, valued at $1.3 billion after a $113 million Series B funding round, provides users with a single platform to ch...
Avalanche (AVAX) price fell 2.39% to $6.34 as most altcoins weakened, making AVAX one of the poorest performers despite a flat overall crypto market. The decline lacks a specific catalyst and reflects broad market risk-off sentiment. However, whale a...
Austrian tax law treats swapping Bitcoin for stablecoins as a tax-neutral crypto-to-crypto transaction if the stablecoin qualifies as a cryptocurrency. This means the tax on Bitcoin gains is deferred, not canceled, with acquisition costs transferring...
The S&P 500 showed remarkable earnings growth in Q2 2026, with earnings per share rising 50.8%, largely due to non-operating investment gains and AI-related capital expenditures. Despite a reasonable forward price-to-earnings ratio of 20.7, the marke...
